Skip to main content
Search

Jannik Lübberstedt

1 related articles

Subscribe to updates
  1. Routine lab trajectories flag cancer complications months ahead: 162 diagnoses, up to 6.1-fold enrichment on the rarest endpoint

    Cancer treatment generates blood panels at nearly every visit, yet single-timepoint prognostic tools discard how those values move over time. A transformer trained on 2,777,595 laboratory measurements from 3905 patients with multiple myeloma or ovarian cancer predicted which of 162 treatment-associated complications would be newly recorded within two years, beating prevalence across all eight clinical categories with 1.5- to 6.1-fold enrichment. Across 91 internal endpoints with at least ten events, mean AUROC was 0.734 versus 0.710 for an engineered-trajectory baseline.

You’re all caught up